Treatments

*September 2024* Monday, September 23, 2024, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported initial Phase 2 data of BDTX-1535. The data demonstrated encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor (EGFR)-mutant (EGFRm) non-small cell lung cancer (NSCLC). “Patients often become resistant to osimertinib with the emergence of…

*September 2024* The investigational HER​​3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) elicited a statistically significant improvement in progression-free survival (PFS) vs platinum-based chemotherapy in patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who were previously exposed to an EGFR TKI, meeting the primary end point of the…

*August 2024* "You're only as old as you feel." Back in 2021, German researchers gave some weight to that expression with a longitudinal study suggesting that feeling "younger" protects middle-age and older adults against damaging stress. Lung cancer is generally viewed as an older person's disease, with an average age…

*August 2024* Abstract Purpose Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab…

*August 2024* The phase 3 LAURA study (NCT03521154) showed that the drug osimertinib (Tagrisso) significantly extends survival for patients with unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutations, a patient group that had previously received a standard treatment of chemotherapy and radiation. LAURA compared osimertinib with placebo in 216 patients.…

*August 2024* Currently, afatinib (Gilotrif) is the only approved treatment for advanced non–small cell lung cancer (NSCLC) with atypical EGFR mutations, including S768I, L861Q, and G719X. However, its effectiveness is limited. Cohort C of the CHRYSALIS-2 study (NCT04077463) investigated the combination of amivantamab (Rybrevant) and lazertinib (Leclaza), which has proven efficacy in more…

*October 2024* The clinical benefits of immune checkpoint inhibitor (ICI)-based treatments in treating individuals with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who have progressed on EGFR tyrosine-kinase inhibitors (TKIs) remain controversial. We aimed to review the literature to comprehensively investigate the individual and comparative clinical outcomes of various ICI-based treatment strategies…

*December 2024* Hello. I'm Mark Kris, from Memorial Sloan Kettering, speaking today about the use of chemotherapy with a targeted therapy, particularly in patients with EGFR and ALK mutations. I'd like to compare and contrast the thoughts about using chemotherapy in the postoperative adjuvant setting vs in the stage IV setting. I think the clearest…

*August 2024* Patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit from treatment with tyrosine kinase inhibitors (TKI) targeting EGFR. Despite improvements in patient care, especially with the 3rd generation TKI osimertinib, disease relapse is observed in all patients. Among the various processes involved in TKI resistance, epithelial-to-mesenchymal transition (EMT) is…

*September 2024* This recorded event will delve into cutting-edge advancements in the diagnosis and treatment of Leptomeningeal Metastases (LM). Greg Fuller, MD, PhD, from The University of Texas MD Anderson Cancer Center and Plus Therapeutics, will kick off the session with an extensive exploration of the neuropathological aspects of Leptomeningeal…